Cite
MLA Citation
A Passaro et al.. “503PActivity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials.” Annals of oncology, vol. 30, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100098040153.0x00003f